Choose Your News
Loading...
Thumbnail
Gilead Sciences is continuing to make major investments in cancer treatments, announcing Thursday that its subsidiary Kite will pay biotech company Sangamo Therapeutics up to... [Read More]
Time and time again, as they conducted hundreds of lab experiments and clinical trials over the last seven years, scientists testing a prescription opioid developed... [Read More]
Preview